All epstein-barr virus articles
-
NewsEpstein-Barr virus hijacks host genome boosting nasopharyngeal carcinoma
Researchers unravel the mechanisms of Epstein-Barr virus (EBV) and host chromatin interactions in nasopharyngeal cancer cells.
-
NewsScientists find weak points on Epstein-Barr virus
Studies of interactions between two lab-generated monoclonal antibodies (mAbs) and an essential Epstein-Barr virus (EBV) protein have uncovered targets that could be exploited in designing treatments and vaccines.
-
NewsMultiple sclerosis: Possible basis for vaccine researched
Researchers have shown that the risk of MS is particularly high in people with a combination of certain host factors and variants of the Epstein-Barr virus (EBV).
-
NewsStudy reveals how the immune system fights to keep herpes at bay
A recent study, conducted using lab-engineered cells, unveils the precise maneuvers used by host and herpes simplex virus (HSV) in the fight for dominance of the cell.
-
NewsGut microbiome can increase risk and severity of HIV and EBV disease
Researchers have shown that the microbiome has a significant impact on the acquisition of Epstein-Barr virus (EBV) and human immunodeficiency virus-1 (HIV) infection and plays a role in the course of disease.
-
NewsKissing down the epochs played role in disease transmission
Romantic kissing was a common practice in ancient times and cannot be regarded as a sudden biological trigger causing a spread of specific pathogens, a new study suggests.
-
NewsBacteria with anti-inflammatory effects found in gut of sclerosis patients with no evidence of active disease
Multiple sclerosis patients do not have the same bacteria in their intestines as healthy people. There are also differences in the composition and function of the bacteria in the intestines of multiple sclerosis patients, depending on whether their illness is active, and whether they are in treatment, a new study shows.
-
NewsExperimental monoclonal antibodies take the fight to Epstein-Barr virus
Researchers have discovered a panel of investigational monoclonal antibodies (mAbs) targeting different sites of the Epstein-Barr virus (EBV) blocked infection when tested in human cells in a laboratory setting.
